Odyssey Group International (ODYY) 10-Q 14 Jun 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Apr. 30, 2022	Jun. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--07-31
Entity File Number	000-56196
Entity Registrant Name	Odyssey Health, Inc.
Entity Central Index Key	0001626644
Entity Tax Identification Number	47-1022125
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2300 West Sahara Avenue
Entity Address, Address Line Two	Suite 800
Entity Address, Address Line Three	#4012
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89102
City Area Code	(702)
Local Phone Number	780-6559
Title of 12(b) Security	Common Stock ($0.001 par value)
Trading Symbol	ODYY
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		84,609,444

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Current assets:
Cash	$ 266,300	$ 556,584
Prepaid expenses and other current assets	308,790	53,535
Total current assets	575,090	610,119
Property and equipment, net of accumulated depreciation of $3,310 and $2,896	0	414
Intangible assets, net of accumulated amortization of $1,206 and $0	44,014	0
Total assets	619,104	610,533
Current liabilities:
Accounts payable	1,057,956	1,224,783
Accrued wages	823,220	259,487
Accrued interest	133,437	32,351
Asset purchase liability	1,123,090	1,125,026
Notes payable, net of unamortized debt discount and closing costs of $88,863 and $351,030	1,561,137	736,240
Total current liabilities	4,698,840	3,377,887
Total liabilities	4,698,840	3,377,887
Commitments and contingencies (Note 5)
Shareholders' deficit:
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.001 par value, 500,000,000 shares authorized 82,876,872 and 88,559,978 shares issued and outstanding	82,878	87,191
Additional paid-in-capital	48,009,467	42,879,278
Accumulated deficit	(52,172,081)	(45,733,823)
Total stockholders' deficit	(4,079,736)	(2,767,354)
Total liabilities and stockholders' deficit	$ 619,104	$ 610,533

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Statement of Financial Position [Abstract]
Accumulated depriciation	$ 3,310	$ 2,896
Accumulated amortization	1,206	0
Unamortized debt discount	$ 88,863	$ 351,030
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	82,876,872	88,559,978
Common Stock, Shares Outstanding	82,876,872	88,559,978

Statements of Operations and Co

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Income Statement [Abstract]
Research and development	$ 63,139	$ 565,764	$ 846,366	$ 608,383
General and administrative expense	2,803,397	2,088,556	5,425,523	3,204,997
In-process research and development	0	9,440,000	0	9,440,000
Loss from operations	(2,866,536)	(12,094,320)	(6,271,889)	(13,253,380)
Interest expense	(232,686)	(357,370)	(658,395)	(779,124)
Other income, net	(49)	50,000	492,026	50,000
Net loss and comprehensive loss	$ (3,099,271)	$ (12,401,690)	$ (6,438,258)	$ (13,982,504)
Basic net loss per share	$ (0.04)	$ (0.13)	$ (0.07)	$ (0.15)
Diluted net loss per share	$ (0.04)	$ (0.13)	$ (0.07)	$ (0.15)
Shares used for basic net loss per share	83,948,500	93,382,540	88,843,353	93,135,527
Shares used for diluted net loss per share	83,948,500	93,382,540	88,843,353	93,135,527

Statements of Stockholder's Equ

Statements of Stockholder's Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jul. 31, 2020	$ 88,560	$ 28,110,689	$ (28,850,728)	$ (651,479)
Beginning balance, shares at Jul. 31, 2020	88,559,978
Conversion of convertible note payable	$ 214	106,786		107,000
Conversion of convertible note payable, shares	214,000
Stock-based compensation		130,301		130,301
Warrants issued in connection with debt financings		128,333		128,333
Common stock issued in debt financing	$ 420	196,980		197,400
Common stock issued in debt financing, shares	420,000
Common stock issued in equity financing	$ 1,396	248,604		250,000
Common stock issued in equity financing, shares	1,396,224
Stock forfeited	$ (20)			(20)
Stock forfeited, shares	(20,000)
Net loss			(711,514)	(711,514)
Ending balance, value at Oct. 31, 2020	$ 90,570	28,921,693	(29,562,242)	(549,979)
Ending balance, shares at Oct. 31, 2020	90,570,202
Beginning balance, value at Jul. 31, 2020	$ 88,560	28,110,689	(28,850,728)	(651,479)
Beginning balance, shares at Jul. 31, 2020	88,559,978
Net loss				(13,982,504)
Ending balance, value at Apr. 30, 2021	$ 101,539	41,784,782	(42,833,232)	(946,911)
Ending balance, shares at Apr. 30, 2021	101,539,105
Beginning balance, value at Oct. 31, 2020	$ 90,570	28,921,693	(29,562,242)	(549,979)
Beginning balance, shares at Oct. 31, 2020	90,570,202
Common stock issued for services	$ 540	69,460		70,000
Common stock issued for services, shares	540,000
Stock-based compensation		111,728		111,728
Common stock issued to LGH in connection with debt financing	$ 300	83,700		84,000
Common stock issued to LGH in connection with debt financing, shares	300,000
Beneficial conversion feature of LGH financing		19,780		19,780
Warrants issued in connection with debt financings		82,720		82,720
Common stock issued in equity financing	$ 200	34,880		35,080
Common stock issued in equity financing, shares	200,000
Net loss			(869,300)	(869,300)
Ending balance, value at Jan. 31, 2021	$ 91,610	29,323,961	(30,431,542)	(1,015,971)
Ending balance, shares at Jan. 31, 2021	91,610,202
Common stock issued for services	$ 100	123,150		123,250
Common stock issued for services, shares	100,000
Stock-based compensation		887,437		887,437
Common stock issued in asset purchase agreement	6,000	8,254,000		8,260,000
Common stock issued in connection with LPC share purchase	1,351	1,185,044		1,186,395
Warrants issued in connection with debt financings		423,003		423,003
Common stock issued in equity financing	$ 1,486	1,213,014		1,214,500
Common stock issued in equity financing, shares	1,485,834
Net loss			(12,401,690)	(12,401,690)
Common stock issued in asset purchase agreement, shares	6,000,000
Conversion of convertible note debt financing	$ 298	245,802		246,100
Conversion of convertible note debt financing, shares	298,165
Conversion of convertible note debt financing in connection with LGH	$ 594	88,506		89,100
Conversion of convertible note debt financing in connection with LGH, shares	594,000
Common stock issued in connection with LPC share purchase, shares	1,350,904
Common stock issued in connection with LGH financing	$ 100	40,865		40,965
Common stock issued in connection with LGH financing, shares	100,000
Ending balance, value at Apr. 30, 2021	$ 101,539	41,784,782	(42,833,232)	(946,911)
Ending balance, shares at Apr. 30, 2021	101,539,105
Beginning balance, value at Jul. 31, 2021	$ 87,191	42,879,278	(45,733,823)	(2,767,354)
Beginning balance, shares at Jul. 31, 2021	87,191,168
Stock-based compensation		533,105		533,105
Common stock issued in debt financing	$ 200	17,518		17,718
Common stock issued in debt financing, shares	200,000
Common stock issued in equity financing	$ 3,974	863,061		867,035
Common stock issued in equity financing, shares	3,974,482
Stock forfeited	$ (350)	350
Stock forfeited, shares	(350,000)
Net loss			(1,646,274)	(1,646,274)
Ending balance, value at Oct. 31, 2021	$ 91,016	44,293,312	(47,380,097)	(2,995,769)
Ending balance, shares at Oct. 31, 2021	91,015,650
Beginning balance, value at Jul. 31, 2021	$ 87,191	42,879,278	(45,733,823)	(2,767,354)
Beginning balance, shares at Jul. 31, 2021	87,191,168
Net loss				(6,438,258)
Ending balance, value at Apr. 30, 2022	$ 82,878	48,009,467	(52,172,081)	(4,079,736)
Ending balance, shares at Apr. 30, 2022	82,876,872
Beginning balance, value at Oct. 31, 2021	$ 91,016	44,293,312	(47,380,097)	(2,995,769)
Beginning balance, shares at Oct. 31, 2021	91,015,650
Stock-based compensation		511,310		511,310
Stock forfeited	$ (8,309)	8,309
Stock forfeited, shares	(8,309,578)
Net loss			(1,692,713)	(1,692,713)
Ending balance, value at Jan. 31, 2022	$ 82,707	44,812,931	(49,072,810)	(4,177,172)
Ending balance, shares at Jan. 31, 2022	82,706,072
Stock-based compensation		430,726		430,726
Common stock issue in connection with Prevacus milestone	$ 1,000	(1,000)
Common stock issue in connection with Prevacus milestone, shares	1,000,000
Common stock issued for consulting services	$ 3,000	1,607,000		1,610,000
Common stock issued for consulting services, shares	3,000,000
Vesting of RSUs	$ 500	(500)
Vesting of RSUs, shares	500,000
Common stock issued in debt financing	$ 100	50,900		51,000
Common stock issued in debt financing, shares	100,000
Common stock issued in equity financing	$ 3,071	1,101,910		1,104,981
Common stock issued in equity financing, shares	3,070,800
Stock forfeited	$ (7,500)	7,500
Stock forfeited, shares	(7,500,000)
Net loss			(3,099,271)	(3,099,271)
Ending balance, value at Apr. 30, 2022	$ 82,878	$ 48,009,467	$ (52,172,081)	$ (4,079,736)
Ending balance, shares at Apr. 30, 2022	82,876,872

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Cash flows from operating activities:
Net loss	$ (6,438,258)	$ (13,982,504)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	1,620	5,413
Stock-based compensation	1,475,141	1,129,446
Stock issued for services	1,610,000	193,250
Amortization of beneficial conversion feature, debt discount and closing costs	555,884	593,787
In-process R& D	0	8,260,000
Financing costs paid with stock	0	169,000
Decrease in asset purchase liability	(1,936)	1,125,026
Gain on forgiveness of long-term debt	0	(50,000)
Changes in operating assets and liabilities:
Increase in prepaid expenses and other current assets	(255,255)	(38,333)
Increase (decrease) in accounts payable	(166,826)	69,457
Increase in accrued wages	563,733	35,170
Increase in accrued interest	101,086	29,056
Net cash used in operating activities	(2,554,811)	(2,461,232)
Cash flows from investing activities:
Purchase of patents	(45,220)	0
Net cash used in investing activities	(45,220)	0
Cash flows from financing activities:
Proceeds from notes payable	375,000	1,565,000
Principal payments made on notes payable	(37,269)	(305,470)
Financing closing costs paid with cash	0	(169,000)
Proceeds from equity financing	1,972,016	2,685,975
Net cash provided by financing activities	2,309,747	3,776,505
Increase (decrease) in cash	(290,284)	1,315,273
Cash:
Beginning of period	556,584	62,952
End of period	266,300	1,378,225
Supplemental disclosure of non-cash information:
Cash paid for interest	954	30,310
Common stock issued for debt financing commitment shares	68,718	197,400
Common stock issued for conversion of notes payable and related accrued interest	0	442,200
Warrants issued in connection with financings	0	634,056
Original issue discount on debt	0	169,200
Stock issued in exchange for closing costs	0	124,965
Beneficial conversion feature recognized	$ 0	$ 19,780

Basis of Presentation and Natur

Basis of Presentation and Nature of Operations	9 Months Ended
	Apr. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Nature of Operations	Note 1. Basis of Presentation and Nature of Operations Name Change On December 1, 2021, we received notice that our name change to Odyssey Health, Inc. was approved by the state of Nevada, where we are incorporated. Basis of Presentation The accompanying financial information of Odyssey Health, Inc., f/k/a Odyssey Group International, Inc., is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The financial information as of July 31, 2021, is derived from our 2021 Annual Report on Form 10-K. The financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2021 Annual Report on Form 10-K filed with the SEC on October 29, 2021. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year. Significant Accounting Policies Our significant accounting policies have not changed during the nine months ended April 30, 2022, from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2021. Nature of Operations Our business model is to develop or acquire unique medical-related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We are developing potentially life-saving technologies: the CardioMap® heart monitoring and screening device; the Save A Life choking rescue device, a unique neurosteroid drug compound intended to treat concussions, and a unique drug compound to treat rare brain disorders in partnership with Prevacus, Inc. To date, none of our product candidates has received regulatory clearance or approval for commercial sale. We plan to license, improve, and develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly, as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required in order to sell in the United States. Going Concern We did not recognize any revenues for the year ended July 31, 2021, or the nine months ended April 30, 2022, and we had an accumulated deficit of $ 52,172,081 266,300 The operating deficit indicates substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. The COVID-19 global pandemic has had an unfavorable impact on our business operations. The pandemic has impacted our ability to get financing, engage third-party vendors and the timing of our clinical trial in Australia. The COVID-19 outbreak has adversely affected the U.S. and global economies and financial markets, which may result in a long-term economic downturn that could negatively affect future performance and our ability to secure additional debt or equity funding. If we are unable to raise additional capital by June 14, 2023, we will adjust our current business plan. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, is it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with LPC. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Apr. 30, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 2. New Accounting Pronouncements ASU 2019-12 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “Income Taxes (Topic 740),” which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption of the amendments is permitted, including adoption in any interim period for which financial statements have not yet been issued. The adoption of ASU 2019-12 effective August 1, 2021, on a prospective basis did not have a material effect on our financial position, results of operations, or cash flows. ASU 2020-06 In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for convertible instruments, reduces complexity for preparers and practitioners and improves the decision usefulness and relevance of the information provided to financial statement users. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We have not yet determined the impact of adopting this standard on our financial position, results of operations or cash flows.

Intangible Assets

Intangible Assets	9 Months Ended
	Apr. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 3. Intangible Assets Intangible assets at April 30, 2022, consisted of costs related to a patent for our PRV-002 drug device combination. Amortization expense was as follows: Schedule of amortization expense Three Months Ended April 30, Nine Months Ended April 30, 2022 2021 2022 2021 Amortization expense $ 754 $ – $ 1,206 $ – Future amortization of intangible assets is as follows: Schedule of future amortization of intangible assets Remainder of fiscal 2022 $ 754 Fiscal 2023 3,015 Fiscal 2024 3,015 Fiscal 2025 3,015 Fiscal 2026 3,015 Thereafter 31,200 Total amortization expense $ 44,014

Asset Purchase Liability

Asset Purchase Liability	9 Months Ended
	Apr. 30, 2022
Asset Purchase Liability
Asset Purchase Liability	Note 4. Asset Purchase Liability In connection with our Asset Purchase Agreement with Prevacus in March 2021, we withheld 1,000,000 shares of our common stock with a value of $1.18 per share for an original value of $ 1,180,000 1,123,090 1,125,026

Fair Value

Fair Value	9 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	Note 5. Fair Value The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the nine months ended April 30, 2022, or the year ended July 31, 2021. The carrying values of cash, prepaid expenses, accounts payable and accrued wages approximate their fair value due to their short maturities. No changes were made to our valuation techniques during the quarter ended April 30, 2022. Contingent Liabilities At April 30, 2022, and July 31, 2021, we had contingent consideration related to the acquisition of intellectual property, know-how and patents for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling $250,000 upon FDA clearance of the device. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). We determined the value was zero at both periods since it is not yet probable that we will file for FDA clearance. We also had contingent consideration at April, 2022 and July 31, 2021 related to milestones in our Asset Purchase Agreement with Prevacus, Inc. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). Based on these reviews, the fair value of the contingent consideration was determined to be zero at both periods as it is not yet probable that any of the milestones will be met. Fixed-Rate Debt We have fixed-rate debt that is reported on our Balance Sheets at carrying value less unamortized debt discount and closing costs. The fair value of our fixed rate debt was calculated using a discounted cash flow methodology with estimated current interest rates based on similar risk profile and duration (Level 2). The carrying value, excluding unamortized debt discount and debt issuance costs, and the fair value of our fixed-rate long-term debt was as follows: Schedule of fixed-rate debt April 30, 2022 July 31, 2021 Carrying value $ 1,650,000 $ 1,087,270 Fair value $ 1,630,618 $ 1,094,212 Non-Financial Assets Non-financial assets, such as Property and equipment and Intangible assets are measured at fair value on a non-recurring basis when events or circumstances indicate that an impairment may have occurred. If we determine these assets to be impaired, they are reported at fair value as calculated during the period. No non-financial assets were recorded at fair value during the nine months ended April 30, 2022, or the fiscal year ended July 31, 2021.

Debt

Debt	9 Months Ended
	Apr. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 6. Debt Promissory Notes On December 21, 2021, and December 22, 2021, we entered into a total of five Promissory Notes (the “Notes”) with three of our directors and two officers. Mr. Joseph Michael Redmond, President and Chief Executive Officer, Ms. Christine M. Farrell, Chief Financial Officer, Mr. Jerome H. Casey, Director, Mr. John P. Gandolfo, Director, and Mr. Ricky W. Richardson, Director, each loaned us $ 25,000 125,000 8 May 31, 2022 Tysadco Partners On August 29, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Tysadco Partners (“Tysadco”) pursuant to which we entered into a $ 250,000 8.0 March 1, 2022 250,000 200,000 17,718 0.30 990,000 On March 31, 2022, the SPA was amended to extend the maturity date to March 1, 2023, 25,000 LGH Amendment On April 5, 2021, we entered into a Securities Purchase Agreement with LGH Investments, LLC (“LGH”) pursuant to which we entered into a $ 1,050,000 8.0 February 1, 2022 February 5, 2022 May 31, 2022 200,000 100,000 51,000 250,000 1.00 1,336,000 Notes Payable The following notes payable were outstanding: Schedule of Notes Payable April 30, 2022 July 31, 2021 Note issued to Labrys due August 14, 2021 with an interest rate of 12% $ – $ 37,270 Convertible note issued to LGH due May 31, 2022 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 12.1%) and convertible at $1.00 per share 1,250,000 1,050,000 Promissory notes issued to officers and directors due September 30, 2022 with a fixed interest rate of 8.0% per annum (see Note 13) 125,000 – Tysadco convertible promissory note payable due March 1, 2023 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 15.2%) and convertible at $0.30 per share 275,000 – 1,650,000 1,087,270 Unamortized debt discount and closing costs (88,863 ) (351,030 ) $ 1,561,137 $ 736,240

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Stock-Based Compensation	Note 7. Stock-Based Compensation 2021 Omnibus Stock Incentive Plan At our annual stockholder meeting held September 14, 2021, the stockholders approved the Amended and Restated 2021 Omnibus Stock Incentive Plan (the “2021 Plan”). The purpose of the Amended and Restated 2021 Omnibus Stock Incentive Plan is to enable us to recruit and retain highly qualified employees, directors and consultants and to provide incentives for productivity and the opportunity to share in the our growth and value. Subject to certain adjustments, the maximum number of shares of common stock, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, cash or other stock-based awards that may be issued under the Amended and Restated 2021 Omnibus Stock Incentive Plan is 20,000,000. At April 30, 2022, 17,725,000 20,000,000 Stock Options Stock option activity during the nine months ended April 30, 2022, was as follows: Schedule of stock option activity Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2021 1,050,000 $ 1.22 Options issued 1,225,000 0.45 Options outstanding at April 30, 2022 2,275,000 0.80 Restricted Stock Units (“RSUs”) RSU activity during the nine months ended April 30, 2022, was as follows: Schedule of RSU activity Number of RSUs Weighted Average Grant Date Fair Value RSUs outstanding at July 31, 2021 4,396,819 $ 1.09 RSUs issued 1,500,000 0.45 RSUs vested (2,792,943 ) 0.61 RSUs outstanding at April 30, 2022 3,103,876 0.28 On September 14, 2021, following the annual stockholders meeting, three re-elected board members were granted 500,000 675,000 Warrants Schedule of warrant activity Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2021 4,739,834 $ 1.05 Warrants issued 3,102,066 0.59 Warrants canceled (1,485,834 ) 1.50 Warrants outstanding at April 30, 2022 6,356,066 0.72 Unrecognized Compensation Costs At April 30, 2022, we had unrecognized stock-based compensation of $ 283,901 0.67

Research and Development Rebate

Research and Development Rebate	9 Months Ended
	Apr. 30, 2022
Research and Development [Abstract]
Research and Development Rebate	Note 8. Research and Development Rebate On November 2, 2021, we received a research and development rebate from the government of Australia in the amount of $ 214,120

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Apr. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Note 9. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Potentially dilutive common stock and common stock equivalents, including stock options, RSUs and warrants are excluded as they would be antidilutive. The following anti-dilutive securities were excluded from the calculations of diluted net loss per share: Schedule of anti-dilutive shares Nine Months Ended April 30, 2022 2021 Options to purchase common stock 2,275,000 900,000 Shares issuable upon conversion of convertible notes and related accrued interest 2,326,000 1,183,691 Warrants to purchase common stock 6,356,066 3,648,334 Unvested restricted stock units 3,103,876 2,113,598 Total potentially dilutive securities 14,060,942 7,845,623

Common Stock

Common Stock	9 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Common Stock	Note 10. Common Stock Returned Shares On August 5, 2021, our loan with Labrys Fund, LP was repaid in full and, per the agreement, on August 6, 2021, 350,000 restricted stock shares were returned to treasury. On December 21, 2021, Vivakor, Inc., a shareholder, returned 3,309,578 On December 29, 2021, Regal Growth, LLC, a shareholder, returned 5,000,000 On February 2, 2022, LBL Professional Consulting, Inc., a shareholder, returned 7,500,000 Shares Issuable Pursuant to our agreement with Prevacus entered into on March 1, 2021, Prevacus earned 1,000,000 Stock Issuance On February 9, 2022, in connection with an investor relations consulting agreement with Tysadco, we issued Tysadco 3,000,000 0.53 Reverse Split At our 2021 annual stockholder meeting, which was held on September 14, 2021, the stockholders approved the proposal that granted the Board discretionary authority to amend our Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of our common stock. As determined by our Board, such stock split could be effected at a time and choosing of the Board. The amendment did not change the number of authorized shares of common stock or preferred stock or the relative voting power of our stockholders. The number of authorized shares will not be reduced. The number of authorized but unissued shares of our common stock will materially increase and will be available for re-issuance. We reserve the right not to effect any reverse stock split if the Board does not deem it to be in the best interests of our stockholders and the Board’s decision as to whether and when to effect the reverse stock split will be based on a number of factors, including prevailing market conditions, existing and expected trading prices for our common stock, actual or forecasted results of operations, and the likely effect of such results on the market price of our common stock. Lincoln Park Securities Purchase Agreement On October 22, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Lincoln Park Capital Fund, LLC (“LPC”) pursuant to which we received $ 250,000 1,500,000 833,333 0.50 5 LPC Purchase Agreement Draws During the nine months ended April 30, 2022, LPC purchased a total of 1,174,482 467,236 4,121,610 8,311,289 15,943,556 Tysadco Partners On October 18, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Tysadco pursuant to which we received $ 250,000 1,500,000 833,333 0.50 5 LGH In connection with an amendment to the LGH Note, we issued LGH 100,000 51,000 Private Placement On February 2, 2022, we entered into an agreement to raise money through a private investment in a public entity (“PIPE”). We offered up to 14,285,714 0.35 5 0.70 The Offering is made on a “Minimum” basis, meaning a minimum amount of money must be raised. The minimum amount of 1,000,000 2,870,800 1,435,400 1,004,780 849,302 In connection with the Offering, we paid Laidlaw & Company (UK) Ltd. (“Laidlaw”), our introducing broker, 10% of the proceeds, or $ 100,478 We are required to file a registration statement for resale of all shares issued or issuable in connection with the Offering within 60 days of the final closing of the Offering. Failure to file a registration statement for the resale of the shares would require us to pay to the purchasers, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to one and one-half percent (1.5%) of the aggregate subscription amount of such purchaser’s securities on the day of failure to file the registration statement and on every thirtieth (30 th

Related Party Transactions

Related Party Transactions	9 Months Ended
	Apr. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Due to Officers The following amounts were due to our officers for reimbursement of expenses and were included in Accounts payable on our Balance Sheets: Schedule of related party payables April 30, 2022 July 31, 2021 Joseph M. Redmond, CEO $ 5,795 $ 2,568 Christine Farrell, CFO 130 – $ 5,925 $ 2,568 The amount of unpaid salary and bonus due to our officers was included in Accrued wages on our Balance Sheets and was as follows: Schedule of accrued wages April 30, 2022 July 31, 2021 Joseph M. Redmond, CEO $ 646,391 $ 183,846 Christine Farrell, CFO 96,971 – $ 743,361 $ 183,846 On January 31, 2022, the Compensation Committee and our full Board approved the 2021 bonus plan. Pursuant to the plan, Mr. Redmond received a $ 360,000 40,000 See also Note 6 for a discussion of $ 25,000

Donation Received

Donation Received	9 Months Ended
	Apr. 30, 2022
Donation Received
Donation Received	Note 12. Donation Received On January 5, 2022, we received a donation in the amount of $ 500,000

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events On May 3, 2022, the second and final closing of the PIPE occurred, pursuant to which we issued one 1,187,572 Units, consisting of 1,187,572 shares of our common stock and warrants to purchase 593,786 shares of our common stock for which we received $415,650 in gross proceeds. As part of the closing, we issued Laidlaw 608,755 warrants with an exercise prices of $0.35 per share with a five-year cashless exercise. In June 2022, the maturity date of the promissory notes outstanding to our officers and directors was extended to September 30, 2022. In June 2022, the maturity date of the LGH Note was extended to August 30, 2022. As consideration, the Note conversion price changed to twenty cents ($0.20) per common share.

Basis of Presentation and Nat_2

Basis of Presentation and Nature of Operations (Policies)	9 Months Ended
	Apr. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial information of Odyssey Health, Inc., f/k/a Odyssey Group International, Inc., is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The financial information as of July 31, 2021, is derived from our 2021 Annual Report on Form 10-K. The financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2021 Annual Report on Form 10-K filed with the SEC on October 29, 2021. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.
Significant Accounting Policies	Significant Accounting Policies Our significant accounting policies have not changed during the nine months ended April 30, 2022, from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2021.
Nature of Operations	Nature of Operations Our business model is to develop or acquire unique medical-related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We are developing potentially life-saving technologies: the CardioMap® heart monitoring and screening device; the Save A Life choking rescue device, a unique neurosteroid drug compound intended to treat concussions, and a unique drug compound to treat rare brain disorders in partnership with Prevacus, Inc. To date, none of our product candidates has received regulatory clearance or approval for commercial sale. We plan to license, improve, and develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly, as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required in order to sell in the United States.
Going Concern	Going Concern We did not recognize any revenues for the year ended July 31, 2021, or the nine months ended April 30, 2022, and we had an accumulated deficit of $ 52,172,081 266,300 The operating deficit indicates substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. The COVID-19 global pandemic has had an unfavorable impact on our business operations. The pandemic has impacted our ability to get financing, engage third-party vendors and the timing of our clinical trial in Australia. The COVID-19 outbreak has adversely affected the U.S. and global economies and financial markets, which may result in a long-term economic downturn that could negatively affect future performance and our ability to secure additional debt or equity funding. If we are unable to raise additional capital by June 14, 2023, we will adjust our current business plan. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, is it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with LPC. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Apr. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of amortization expense	Schedule of amortization expense Three Months Ended April 30, Nine Months Ended April 30, 2022 2021 2022 2021 Amortization expense $ 754 $ – $ 1,206 $ –
Schedule of future amortization of intangible assets	Schedule of future amortization of intangible assets Remainder of fiscal 2022 $ 754 Fiscal 2023 3,015 Fiscal 2024 3,015 Fiscal 2025 3,015 Fiscal 2026 3,015 Thereafter 31,200 Total amortization expense $ 44,014

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of fixed-rate debt	Schedule of fixed-rate debt April 30, 2022 July 31, 2021 Carrying value $ 1,650,000 $ 1,087,270 Fair value $ 1,630,618 $ 1,094,212

Debt (Tables)

Debt (Tables)	9 Months Ended
	Apr. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Schedule of Notes Payable April 30, 2022 July 31, 2021 Note issued to Labrys due August 14, 2021 with an interest rate of 12% $ – $ 37,270 Convertible note issued to LGH due May 31, 2022 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 12.1%) and convertible at $1.00 per share 1,250,000 1,050,000 Promissory notes issued to officers and directors due September 30, 2022 with a fixed interest rate of 8.0% per annum (see Note 13) 125,000 – Tysadco convertible promissory note payable due March 1, 2023 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 15.2%) and convertible at $0.30 per share 275,000 – 1,650,000 1,087,270 Unamortized debt discount and closing costs (88,863 ) (351,030 ) $ 1,561,137 $ 736,240

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Apr. 30, 2022
Equity [Abstract]
Schedule of stock option activity	Schedule of stock option activity Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2021 1,050,000 $ 1.22 Options issued 1,225,000 0.45 Options outstanding at April 30, 2022 2,275,000 0.80
Schedule of RSU activity	Schedule of RSU activity Number of RSUs Weighted Average Grant Date Fair Value RSUs outstanding at July 31, 2021 4,396,819 $ 1.09 RSUs issued 1,500,000 0.45 RSUs vested (2,792,943 ) 0.61 RSUs outstanding at April 30, 2022 3,103,876 0.28
Schedule of warrant activity	Schedule of warrant activity Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2021 4,739,834 $ 1.05 Warrants issued 3,102,066 0.59 Warrants canceled (1,485,834 ) 1.50 Warrants outstanding at April 30, 2022 6,356,066 0.72

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Apr. 30, 2022
Earnings Per Share [Abstract]
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares Nine Months Ended April 30, 2022 2021 Options to purchase common stock 2,275,000 900,000 Shares issuable upon conversion of convertible notes and related accrued interest 2,326,000 1,183,691 Warrants to purchase common stock 6,356,066 3,648,334 Unvested restricted stock units 3,103,876 2,113,598 Total potentially dilutive securities 14,060,942 7,845,623

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Apr. 30, 2022
Related Party Transactions [Abstract]
Schedule of related party payables	Schedule of related party payables April 30, 2022 July 31, 2021 Joseph M. Redmond, CEO $ 5,795 $ 2,568 Christine Farrell, CFO 130 – $ 5,925 $ 2,568
Schedule of accrued wages	Schedule of accrued wages April 30, 2022 July 31, 2021 Joseph M. Redmond, CEO $ 646,391 $ 183,846 Christine Farrell, CFO 96,971 – $ 743,361 $ 183,846

Basis of Presentation and Nat_3

Basis of Presentation and Nature of Operations (Details Narrative) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 52,172,081	$ 45,733,823
Cash and cash equivalents	$ 266,300

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 754	$ 0	$ 1,206	$ 0

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of fiscal 2022	$ 754
Fiscal 2023	3,015
Fiscal 2024	3,015
Fiscal 2025	3,015
Fiscal 2026	3,015
Thereafter	31,200
Total amortization expense	$ 44,014	$ 0

Asset Purchase Liability (Detai

Asset Purchase Liability (Details Narrative) - USD ($)	Apr. 30, 2022	Jul. 31, 2021	Mar. 31, 2021
Assets Sold under Agreements to Repurchase [Line Items]
Assets Sold under Agreements to Repurchase, Repurchase Liability	$ 1,123,090	$ 1,125,026
Prevacus [Member]
Assets Sold under Agreements to Repurchase [Line Items]
Assets Sold under Agreements to Repurchase, Repurchase Liability			$ 1,180,000

Fair Value (Details)

Fair Value (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Fair Value Disclosures [Abstract]
Carrying value	$ 1,650,000	$ 1,087,270
Fair value	$ 1,630,618	$ 1,094,212

Debt (Details)

Debt (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Debt Instrument [Line Items]
Notes Payable	$ 1,650,000	$ 1,087,270
Unamortized debt discount and closing costs	(88,863)	(351,030)
Notes Payable current	1,561,137	736,240
Notes [Member] | Labrys [Member]
Debt Instrument [Line Items]
Notes Payable	0	37,270
Notes [Member] | Tysadco [Member]
Debt Instrument [Line Items]
Notes Payable	275,000	0
Convertible Notes [Member] | L G H [Member]
Debt Instrument [Line Items]
Notes Payable	1,250,000	1,050,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Notes Payable	$ 125,000	$ 0

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)

Feb. 02, 2022

Mar. 31, 2022

Feb. 15, 2022

Aug. 29, 2021

Apr. 05, 2021

Apr. 30, 2022

Oct. 31, 2021

Apr. 30, 2021

Jan. 31, 2021

Oct. 31, 2020

Apr. 30, 2022

Jul. 31, 2021

Debt Instrument [Line Items]

Stock issued new, shares

14,285,714

Stock issued new, value

$ 1,104,981

$ 867,035

$ 1,214,500

$ 35,080

$ 250,000

Consideration amount

1,650,000

$ 1,650,000

$ 1,087,270

Tysadco Partners [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Maturity date

Mar. 1, 2023

Mar. 1, 2022

Debt face amount

$ 250,000

Debt interest rate

8.00%

Proceeds from issuance of debt

$ 250,000

Stock issued new, shares

200,000

Stock issued new, value

$ 17,718

Conversion price per share

$ 0.30

Debt converted, shares issued

990,000

Consideration amount

$ 25,000

LGH Amendment [Member] | Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Maturity date

Feb. 1, 2022

LGH Amendment [Member] | Convertible Promissory Note [Member] | Minimum [Member]

Debt Instrument [Line Items]

Maturity date

Feb. 5, 2022

LGH Amendment [Member] | Convertible Promissory Note [Member] | Maximum [Member]

Debt Instrument [Line Items]

Maturity date

May 31, 2022

LGH Amendment [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Debt face amount

$ 1,050,000

Debt interest rate

8.00%

Stock issued new, shares

100,000

Stock issued new, value

$ 51,000

Conversion price per share

$ 1

Debt converted, shares issued

1,336,000

Consideration amount

$ 200,000

Proceeds from other debt

$ 250,000

The Notes [Member]

Debt Instrument [Line Items]

Proceeds from Debt

$ 125,000

Interest rate

8.00%

Maturity date

May 31, 2022

The Notes [Member] | Redmond [Member]

Debt Instrument [Line Items]

Loans payable

25,000

$ 25,000

The Notes [Member] | Farrell [Member]

Debt Instrument [Line Items]

Loans payable

25,000

25,000

The Notes [Member] | Casey [Member]

Debt Instrument [Line Items]

Loans payable

25,000

25,000

The Notes [Member] | Gandolfo [Member]

Debt Instrument [Line Items]

Loans payable

25,000

25,000

The Notes [Member] | Richardson [Member]

Debt Instrument [Line Items]

Loans payable

$ 25,000

$ 25,000

Stock-Based Awards (Details - S

Stock-Based Awards (Details - Stock Option Activity)	9 Months Ended
	Apr. 30, 2022$ / sharesshares
Equity [Abstract]
Options outstanding at begining balance | shares	1,050,000
Weighted Average Exercise Price at beginning balance | $ / shares	$ 1.22
Options issued | shares	1,225,000
Options issued | $ / shares	$ 0.45
Options outstanding at ending balance | shares	2,275,000
Weighted Average Exercise Price at ending balance | $ / shares	$ 0.80

Stock-Based Awards (Details - R

Stock-Based Awards (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Apr. 30, 2022$ / sharesshares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Beginning balance | shares	4,396,819
Weighted Average Beginning balance | $ / shares	$ 1.09
RSUs issued | shares	1,500,000
Weighted Average Grant Date Fair Value Issued, issued | $ / shares	$ 0.45
RSUs vested | shares	(2,792,943)
Weighted Average Grant Date Fair Value Vested, vested | $ / shares	$ 0.61
Number of Shares Ending balance | shares	3,103,876
Weighted Average Ending balance | $ / shares	$ 0.28

Share-Based Awards (Details - W

Share-Based Awards (Details - Warrant Activity) - Warrant [Member]	9 Months Ended
	Apr. 30, 2022$ / sharesshares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Beginning balance | shares	4,739,834
Weighted Average Beginning balance | $ / shares	$ 1.05
Warrants issued | shares	3,102,066
Weighted average exercise price, warrants issued | $ / shares	$ 0.59
Warrants canceled | shares	(1,485,834)
Weighted average exercise price, warrants canceled | $ / shares	$ 1.50
Number of Shares Ending balance | shares	6,356,066
Weighted Average Ending balance | $ / shares	$ 0.72

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	Sep. 14, 2021	Apr. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation		$ 283,901
Weighted average remaining vesting period		8 months 1 day
Restricted Stock Units (RSUs) [Member] | Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted	$ 500,000
Fair value of options granted	$ 675,000
Omnibus Stock Incentive Plan 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for grant		17,725,000
Number of shares reserved		20,000,000

Research and Development Reba_2

Research and Development Rebate (Details Narrative)	3 Months Ended
	Nov. 02, 2021USD ($)
Research and Development [Abstract]
Research and development expense	$ 214,120

Net Loss Per Share (Details - A

Net Loss Per Share (Details - Antidilutive shares) - shares	9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	14,060,942	7,845,623
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,275,000	900,000
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,326,000	1,183,691
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	6,356,066	3,648,334
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	3,103,876	2,113,598

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)

Apr. 14, 2022

Feb. 09, 2022

Feb. 02, 2022

Oct. 22, 2021

Oct. 18, 2021

Oct. 18, 2021

Apr. 30, 2022

Oct. 31, 2021

Apr. 30, 2021

Jan. 31, 2021

Oct. 31, 2020

Dec. 29, 2021

Dec. 21, 2021

Apr. 30, 2022

Jul. 31, 2021

Mar. 01, 2021

Class of Stock [Line Items]

Shares issued

1,000,000

Issuance of shares

14,285,714

Issuance of shares value

$ 1,104,981

$ 867,035

$ 1,214,500

$ 35,080

$ 250,000

Sale of stock per share

$ 0.35

Minimum amount

$ 1,000,000

Units issued

2,870,800

2,870,800

Net proceeds

$ 849,302

Cash

$ 266,300

$ 266,300

$ 556,584

Investor [Member]

Class of Stock [Line Items]

Units issued

1,435,400

1,435,400

Proceeds from warrant issued

$ 1,004,780

LPC Purchase Agreement [Member]

Class of Stock [Line Items]

Proceeds from Issuance of Common Stock

$ 467,236

Issuance of shares

1,174,482

Common Stock, Other Shares, Outstanding

4,121,610

4,121,610

Remaining purchase availability

$ 8,311,289

$ 8,311,289

Remaining purchase availability shares

15,943,556

15,943,556

Investor Warrants [Member]

Class of Stock [Line Items]

Exercise per share

$ 0.70

Warrants term

5 years

Tysadco [Member]

Class of Stock [Line Items]

Price per share

$ 0.53

Tysadco [Member] | Restricted Stock [Member]

Class of Stock [Line Items]

Issuance of restricted shares

3,000,000

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Proceeds from Issuance of Common Stock

$ 250,000

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]

Class of Stock [Line Items]

Issuance of shares

1,500,000

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member] | Warrants [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

833,333

Exercise per share

$ 0.50

Warrants term

5 years

Tysadco Partners [Member] | Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Proceeds from Issuance of Common Stock

$ 250,000

Tysadco Partners [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]

Class of Stock [Line Items]

Issuance of shares

1,500,000

Tysadco Partners [Member] | Securities Purchase Agreement [Member] | Warrants [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

833,333

Exercise per share

$ 0.50

$ 0.50

Warrants term

5 years

5 years

L G H [Member]

Class of Stock [Line Items]

Issuance of shares

100,000

Issuance of shares value

$ 51,000

Laidlaw [Member]

Class of Stock [Line Items]

Cash

$ 100,478

$ 100,478

Vivakor Inc [Member]

Class of Stock [Line Items]

Treasury stock, shares

3,309,578

Regal Growth LLC [Member]

Class of Stock [Line Items]

Treasury stock, shares

5,000,000

LBL Professional Consulting, Inc [Member]

Class of Stock [Line Items]

Treasury stock, shares

7,500,000

Related Party Transactions (Det

Related Party Transactions (Details - Due to officers) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	$ 5,925	$ 2,568
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	5,795	2,568
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	$ 130	$ 0

Related Party Transactions (D_2

Related Party Transactions (Details - Accrued Compensation) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	$ 743,361	$ 183,846
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	646,391	183,846
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	$ 96,971	$ 0

Related Party Transactions (D_3

Related Party Transactions (Details Narrative) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Related Party Transaction [Line Items]
Notes payable	$ 1,650,000	$ 1,087,270
Mr Redmond [Member]
Related Party Transaction [Line Items]
Bonus paid	360,000
Ms Farrell [Member]
Related Party Transaction [Line Items]
Bonus paid	40,000
Officers and Directors [Member]
Related Party Transaction [Line Items]
Notes payable	$ 25,000

Donation Received (Details Narr

Donation Received (Details Narrative)	Jan. 05, 2022USD ($)
Donation Received
Other income	$ 500,000